Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PHRENILIN FORTE vs PENTOTHAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.
Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.
Tension-type headache
Induction of general anesthesia,Induction of coma for increased intracranial pressure,Status epilepticus (off-label)
1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.
Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.
Butalbital: 35-50 hours (long-acting barbiturate). Acetaminophen: 2-3 hours (therapeutic doses); prolonged in overdose. Caffeine: 3-7 hours (average 5 hours); prolonged in liver disease.
Terminal elimination half-life is 5-12 hours (mean 8 hours) in adults. Prolonged with hepatic impairment, obesity, or high doses due to saturation of redistribution and metabolism.
Butalbital: primarily hepatic via CYP2C19 and CYP2C9. Acetaminophen: hepatic via glucuronidation (UGT1A1, UGT1A9, UGT2B15), sulfation, and CYP2E1 (minor). Caffeine: hepatic via CYP1A2.
Hepatic; primarily via CYP2C9 and other CYP450 enzymes.
Butalbital: ~60-70% renal as unchanged drug and metabolites. Acetaminophen: ~85% renal as sulfate and glucuronide conjugates (2-4% unchanged). Caffeine: ~1% renal unchanged; major metabolites are paraxanthine, theobromine, and theophylline eliminated renally.
Hepatic metabolism (approx. 80%), renal excretion of metabolites (20-30%) and unchanged drug (0.3-1%). Biliary/fecal elimination is negligible.
Butalbital: ~30% bound to plasma proteins. Acetaminophen: <5% bound at therapeutic levels. Caffeine: ~35% bound to albumin.
Approximately 72-86% bound, primarily to albumin (with some binding to lipoproteins).
Butalbital: ~0.8 L/kg (widely distributed). Acetaminophen: ~1 L/kg. Caffeine: ~0.6 L/kg.
Vd = 1.0-2.5 L/kg (mean 1.5 L/kg). High Vd due to extensive tissue distribution, including brain and fat; correlates with high lipid solubility.
Oral bioavailability: Butalbital 90% (well absorbed); Acetaminophen 85-95%; Caffeine 99% (essentially complete).
IV: 100%. Rectal: approximately 60-80% (with variability). IM: approximately 60-70%. Oral: negligible due to extensive first-pass metabolism (not used clinically).
Not formally established. Acetaminophen component: avoid in severe renal impairment (Cr Cl <10 m L/min) due to accumulation of metabolites; adjust dosing interval to every 6 hours for Cr Cl 10-50 m L/min.
No specific GFR-based adjustment; use with caution in severe renal impairment due to prolonged effects.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B): reduce dose to 1 capsule every 6 hours and monitor for hepatotoxicity.
Reduce dose by 50% in Child-Pugh B and C; monitor for prolonged sedation.
Not recommended for pediatric patients due to risk of butalbital dependence and acetaminophen hepatotoxicity. Alternative agents preferred.
Induction: 5-6 mg/kg IV; Maintenance: 1-2 mg/kg IV as needed; Rectal: 25 mg/kg (max 1.5 g).
Initiate at 1 capsule every 6 hours; maximum 4 capsules daily. Renal and hepatic function should be monitored, and dose adjusted accordingly.
Reduce induction dose to 2-3 mg/kg IV; use lower maintenance doses; increased risk of hypotension and respiratory depression.
Acetaminophen may cause severe hepatic injury, including acute liver failure, sometimes resulting in liver transplant or death. Butalbital is habit forming and may be abused; limit use to intermittent treatment.
WARNING: RESPIRATORY DEPRESSION AND APNEA; RESUSCITATIVE EQUIPMENT AND PERSONNEL MUST BE IMMEDIATELY AVAILABLE. INTRA-ARTERIAL INJECTION MAY CAUSE ARTERIAL SPASM, THROMBOSIS, AND GANGRENE.
Hepatotoxicity with acetaminophen overdose; avoid exceeding 4 g/day. Risk of dependence, abuse, and withdrawal with butalbital. CNS depression; avoid alcohol and other sedatives. Renal impairment, hepatic impairment.
Respiratory depression, hypotension, laryngospasm, bronchospasm, cardiac arrhythmias, extravasation risk, and acute porphyria exacerbation.
Hypersensitivity to any component; porphyria; severe hepatic impairment; concomitant MAO inhibitor use (or within 14 days)
Hypersensitivity to barbiturates, acute porphyria, severe respiratory or cardiovascular instability, and inadequate airway management capability.
Avoid alcohol and caffeine-containing foods/drinks (e.g., coffee, tea, cola, chocolate) as they may increase side effects like jitteriness or insomnia. Grapefruit juice may alter caffeine metabolism; consider avoiding. No significant food interactions with acetaminophen or butalbital.
No specific food interactions. However, avoid alcohol for at least 24 hours due to additive CNS depression.
First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third trimester: Butalbital may cause fetal dependence and withdrawal; acetaminophen safe at therapeutic doses. Avoid in pregnancy unless benefit outweighs risk.
PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk. Third trimester: prolonged maternal administration may cause neonatal respiratory depression, hypotonia, and withdrawal. Use only if clearly needed.
Acetaminophen: minimal excretion, M/P ratio ~0.9, considered compatible. Butalbital: excreted in breast milk, M/P ratio ~0.6, may cause infant drowsiness or withdrawal; caution advised. Caffeine: M/P ratio ~0.5-0.8, generally safe in moderate amounts.
Thiopental is excreted in breast milk. M/P ratio is approximately 0.4–0.8. Infant dose is low (<1% of maternal weight-adjusted dose), but caution is advised due to potential CNS depression. American Academy of Pediatrics considers compatible with breastfeeding, but monitor infant for sedation.
Increased renal clearance and volume of distribution in pregnancy may reduce acetaminophen and caffeine levels; no standard dose adjustment recommended. Butalbital: increased clearance due to hepatic enzyme induction and increased Vd; monitor for reduced efficacy; adjust dose based on clinical response. Avoid supratherapeutic doses.
Pregnancy may increase volume of distribution and clearance, but dosing adjustments for thiopental are not routinely recommended. Use lowest effective dose due to increased sensitivity to barbiturates. For cesarean section, standard induction doses (3-5 mg/kg IV) are used; reduced doses may be needed if combined with other sedatives.
Phrenilin Forte is a combination of butalbital, acetaminophen, and caffeine used for tension-type headaches. Butalbital is a barbiturate with high abuse potential; limit to short-term use. Acetaminophen hepatotoxicity risk increases with chronic alcohol use. Caffeine may exacerbate anxiety or insomnia. Monitor for signs of dependence or withdrawal. Avoid in patients with porphyria or severe hepatic impairment.
Pentothal (thiopental) is an ultra-short-acting barbiturate used for induction of anesthesia. It causes dose-dependent respiratory depression and hypotension. Administer only in a controlled setting with resuscitation equipment. Note that it is highly alkaline (p H 10-11) and extravasation causes severe tissue necrosis. Also, it is contraindicated in porphyria.
Take only as prescribed; do not exceed recommended dose due to risk of liver damage from acetaminophen.,Avoid alcohol while taking this medication to prevent liver toxicity.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Do not use with other products containing acetaminophen to avoid overdose.,If you have a history of substance abuse, inform your doctor; this drug can be habit-forming.,Notify your doctor if you experience signs of liver problems (e.g., yellowing of skin/eyes, dark urine) or symptoms of withdrawal (e.g., anxiety, insomnia, tremors).,Store at room temperature away from moisture and heat.
You will receive this medication only under the supervision of an anesthesiologist.,It will cause you to fall asleep quickly and you may feel drowsy for several hours after the procedure.,Do not drive or operate machinery for at least 24 hours after receiving this medication.,Inform your doctor if you have a history of porphyria, liver disease, or allergies to barbiturates.,You may experience a bad taste or cough upon injection.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PHRENILIN FORTE vs PENTOTHAL, answered by our medical review team.
PHRENILIN FORTE is a Barbiturate Combination Analgesic that works by Butalbital: barbiturate that enhances GABA-A receptor activity, causing CNS depression. Acetaminophen: analgesic and antipyretic via COX inhibition and central action. Caffeine: adenosine receptor antagonist, CNS stimulant.. PENTOTHAL is a Barbiturate Anesthetic that works by Potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission; also reduces excitatory glutamate signaling.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PHRENILIN FORTE and PENTOTHAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PHRENILIN FORTE is: 1 capsule (butalbital 50 mg, acetaminophen 325 mg, caffeine 40 mg) orally every 4 hours as needed; maximum 6 capsules per day.. The standard adult dose of PENTOTHAL is: Induction: 3-5 mg/kg IV; Maintenance: 25-75 mg IV as needed; Rectal: 25 mg/kg (max 1.5 g) for induction.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PHRENILIN FORTE and PENTOTHAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PHRENILIN FORTE is classified as Category C. First trimester: Butalbital (barbiturate) associated with oral clefts, neural tube defects; acetaminophen generally safe, but high doses may cause oxidative stress. Second/third tr. PENTOTHAL is classified as Category C. PENTOTHAL (thiopental) crosses the placenta. First trimester: limited human data, animal studies show no consistent teratogenicity. Second trimester: no specific malformation risk.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.